Analysts have clear opinions on REGN.

There are 11 analysts on the Wall offering 12 month price targets for Regeneron in the last 3 months. The average price target is $396.33 with a high forecast of $450.00 and a low forecast of $352.00. The average price target represents a 11.14% increase from the last price of $356.60.
Regeneron Pharmaceuticals, Inc. (REGN) is followed by 11 analysts on the street.

Hartaj Singh from Oppenheimer rates it a Buy with a target of $450.00.

Similarly, 6 days ago Matthew Harrison of Morgan Stanley Reiterated a Hold with a target of $411.00.

The consensus on the street is Moderate Buy.

What does Regeneron Pharmaceuticals, Inc.(REGN) do ?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc. (REGN) Insider Trades

Multiple company employees have indulged in significant insider trading. Regeneron Pharmaceuticals, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Dir, Sing George L : S – Sale+OE(-$5,579,700) of REGN in the trading session of 2020-01-02.

VP Controller Fenimore Christopher R. : S – Sale+OE(-$632,665) of REGN in the trading session of 2019-12-13.

COB Vagelos P Roy : S – Sale+OE(-$19,494,489) of Regeneron Pharmaceuticals, Inc. in the trading session of 2019-12-13.

Looking for stocks just like REGN?

Based on Wall Street analyst research, several stocks are similar to REGN
They are:
– TEVA [Info can be found here: ]
– NVS [Info can be found here: ]
– ALIM [Info can be found here: ]